Drugs of Abuse Testing Assays
6-Acetylmorphine (6-AM)
AB-PINACA
- ARK AB-PINACA Assay
- Immunalysis Synthetic Cannabinoids-3 HEIA
- Immunalysis Amphetamines HEIA
- Immunalysis Barbiturates HEIA
- Immunalysis Benzoylecgonine HEIA
- Immunalysis Cannabinoids HEIA
- Immunalysis Carisoprodol HEIA
- ARK EDDP Assay
- Immunalysis EDDP Specific HEIA
Ethylglucuronide (EtG)
Fentanyl
JWH-018
- ARK UR144/JWH-018 Assay
- Immunalysis Synthetic Cannabinoids-1 HEIA
Ketamine
Meperidine
- ARK Meperidine Assay
- Immunalysis Meperidine HEIA
Methamphetamine
- Immunalysis Methamphetamine HEIA
Methylphenidate-Metabolite
Opiates
- Immunalysis Opiates HEIA
Oxycodone
- Immunalysis Oxycodone HEIA
Phencyclidine (PCP)
- Immunalysis Phencyclidine HEIA
Pregabalin
Tapentadol
- Immunalysis Tapentadol HEIA
Tramadol
- ARK Diagnostics Tramadol Assay
- Immunalysis Tramadol HEIA
UR-144 / XLR-11
- ARK UR144/JWH-018 Assay
- Immunalysis Synthetic Cannabinoids-2 HEIA
Zolpidem
- Immunalysis Zolpidem HEIA
ARK Pregabalin II Assay
The ARK Pregabalin II Assay provides a reliable and fast method for detecting pregabalin in urine. This innovative homogeneous enzyme immunoassay serves as a straightforward alternative to more complex chromatographic methods, making it particularly useful for monitoring potential cases of pregabalin abuse. Its compatibility with major clinical-chemistry systems allows for easy integration into current drug screening processes.
Assay Characteristics
- Rapid and convenient screening method
- Highly specific method for the determination of pregabalin in human urine
- No cross-reactivity with gabapentin at 5,000 µg/mL
- No cross-reactivity with L-amino acids at 200 µg/mL
- Tested endogenous compounds did not show any interference with the assay
- Liquid, ready-to-use reagents, calibrators and controls
- Storage at 2-8°C
- On-board stability for at least 60 days
- Application protocols for all major clinical chemistry analyzers
Background
Pregabalin is an anticonvulsant that was developed as a successor to gabapentin, to which it is structurally closely related. It is the drug of choice for central and peripheral neuropathic disorders and is also used in the treatment of fibromyalgia and certain forms of epilepsy.
Pregabalin is 92-99% excreted unchanged in the urine, with a half-life of around 6 to 7 hours. Despite an officially low potential for abuse, there are increasing publications on actual abuse, especially in patients with previous addictions. Regular use can lead to tolerance and dependence, accompanied by severe withdrawal symptoms.
Side effects include euphoria, relaxation, a significant increase in self-esteem, loss of inhibitions, concentration disorders, dizziness, and visual disturbances. In combination with alcohol, benzodiazepines, or opioids, these effects can be potentiated.